Posted by Michael Wonder on 14 Apr 2020
Alnylam receives fast track designation for vutrisiran for the treatment of the polyneuropathy of hATTR amyloidosis
14 April 2020 - Alnylam Pharmaceuticals announced today that the U.S. FDA has granted fast track designation to vutrisiran, an investigational therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
With this designation, Alnylam will be eligible to submit a rolling new drug application for vutrisiran.
